Over the past 20 years, LABDOM has developed a portfolio of distinct and prestige brands that have revolutionized the skincare, health and wellness industry. I am proud to announce that as of 1st March 2015, NexGen Biopharma LTD. (NEXGEN) a Hong Kong based entity has acquired several of LABDOM’s leading international brands, namely, MFIII, SwissCell Ltd, VitaSwiss Ltd and LAB RMS Ltd predominantly for the nutritional supplements and aesthetic skincare products.
As a wholly owned holding company of Geoffrey Allan Holdings Inc. (GAH), NEXGEN aspires to leverage on an international team of skilled entrepreneurs and leadership vision that will help the growth and expansion of theses brands in to new territories and continents.
To help make this vision a reality, NEXGEN has acquired the existing employees from LAB DOM AVMM SUISSE (ASIA) Sdn. Bhd. into NEXGEN’s wholly-owned Malaysian subsidiary NXG Shared Services Sdn. Bhd. These teams of talented workforce who will remain based at the same premises, in Kota Kinabalu, Sabah, have been mandated to service all current and new global corporate accounts, new distributorship appointments, marketing, billings and fulfillment and can be reached at corp-acctnxgsharedservices.com. I would like to take this opportunity to inform currents distributors that all signed contracts will see their terms and conditions upheld till its expiry date.
I am confident that with this new development, NEXGEN will be able to grow consumer desire and capture expansion opportunities around the world, while matching products to marketplace through a more focused and curated brand portfolio, whilst anticipating global challenges with proficient responses.
Over the next few months, the team at NXG Shared Services and I look forward to working with you as we embark to streamline operational processes that will allow us to provide you with new and improved services levels to ensure that you obtain the best possible support required. And with that in mind, I look forward to a mutual and prosperous working relationship.’
For and on behalf of Nexgen Biopharma Ltd.
Group Operating Officer